JO3256B1 - صياغات من مركبات عضوية - Google Patents

صياغات من مركبات عضوية

Info

Publication number
JO3256B1
JO3256B1 JOP/2014/0069A JOP20140069A JO3256B1 JO 3256 B1 JO3256 B1 JO 3256B1 JO P20140069 A JOP20140069 A JO P20140069A JO 3256 B1 JO3256 B1 JO 3256B1
Authority
JO
Jordan
Prior art keywords
formulations
organic compounds
pharmaceutically acceptable
relates
present
Prior art date
Application number
JOP/2014/0069A
Other languages
English (en)
Inventor
Kochhar Charu
Quinton Jacques
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3256B1 publication Critical patent/JO3256B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136Balloons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/1204Type of occlusion temporary occlusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M25/1002Balloon catheters characterised by balloon shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices
    • A61B2017/12054Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12068Details concerning the detachment of the occluding device from the introduction device detachable by heat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices
    • A61B2017/12054Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12086Details concerning the detachment of the occluding device from the introduction device magnetically detachable

Abstract

يتعلق الاختراع الحالي بتركيبات صيدلانية صلبة تتضمن مثبط الفوسفاتيديل إنوسيتول 3-كيناز المركب 4-(ثلاثي فلورو ميثيل) -5-(6،2-ثنائي مورفولينو بيريميدنـ-4-ـيل) بيريدينـ-2-امين أو ملح منه مقبول صيدلانيا، فيومارات ستياريل صوديوم ، واختياريا ناقل واحد على الأقل مقبول صيدلانيا. يتعلق الاختراع الحالي أيضا بعمليات لتحضيرهم واستخدامهم كأدوية لعلاج السرطان.
JOP/2014/0069A 2013-03-06 2014-03-04 صياغات من مركبات عضوية JO3256B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361773492P 2013-03-06 2013-03-06

Publications (1)

Publication Number Publication Date
JO3256B1 true JO3256B1 (ar) 2018-09-16

Family

ID=50342366

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0069A JO3256B1 (ar) 2013-03-06 2014-03-04 صياغات من مركبات عضوية

Country Status (29)

Country Link
US (2) US9474534B2 (ar)
EP (1) EP2964200B1 (ar)
JP (1) JP6313343B2 (ar)
KR (1) KR102233757B1 (ar)
CN (1) CN105073099B (ar)
AR (1) AR095032A1 (ar)
AU (1) AU2014224238B2 (ar)
BR (1) BR112015021097B1 (ar)
CA (1) CA2904032C (ar)
CL (1) CL2015002466A1 (ar)
EA (1) EA028301B1 (ar)
ES (1) ES2634020T3 (ar)
HK (1) HK1212244A1 (ar)
IL (1) IL240579B (ar)
JO (1) JO3256B1 (ar)
MA (1) MA38358B1 (ar)
MX (1) MX370175B (ar)
MY (1) MY174648A (ar)
NZ (1) NZ711015A (ar)
PE (1) PE20151607A1 (ar)
PH (1) PH12015501945B1 (ar)
PL (1) PL2964200T3 (ar)
PT (1) PT2964200T (ar)
SG (1) SG11201506392VA (ar)
TN (1) TN2015000386A1 (ar)
TW (1) TW201442712A (ar)
UA (1) UA114948C2 (ar)
WO (1) WO2014136048A1 (ar)
ZA (1) ZA201505830B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498604B2 (en) 1997-11-12 2016-11-22 Genesis Technologies Llc Medical device and method
US9561094B2 (en) 2010-07-23 2017-02-07 Nfinium Vascular Technologies, Llc Devices and methods for treating venous diseases
CN105792879A (zh) 2014-06-04 2016-07-20 恩菲纽姆血管技术有限公司 低径向力血管设备和闭塞方法
HRP20240045T1 (hr) * 2015-06-30 2024-03-29 Genentech, Inc. Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta
US20220096094A1 (en) * 2020-09-27 2022-03-31 Boston Scientific Scimed, Inc. Expandable guide devices, systems, and methods
US20220249813A1 (en) * 2021-02-05 2022-08-11 Devaraj Pyne Detachable balloon embolization device and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713849B2 (en) * 1995-12-27 1999-12-09 Janssen Sciences Ireland Uc Bioadhesive solid dosage form
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
DE69941894D1 (de) * 1998-02-10 2010-02-25 Artemis Medical Inc Okklusions-, verankerungs-, span- oder stromsteuergerät
US6066157A (en) 1998-09-16 2000-05-23 Medtronics Ave, Inc. Anchor joint for coaxial balloon dilatation catheter
US6368338B1 (en) 1999-03-05 2002-04-09 Board Of Regents, The University Of Texas Occlusion method and apparatus
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7618435B2 (en) * 2003-03-04 2009-11-17 Nmt Medical, Inc. Magnetic attachment systems
JO2660B1 (ar) * 2006-01-20 2012-06-17 نوفارتيس ايه جي مثبطات الكاينيز Pi-3 وطرق استخدامها
WO2010027921A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
AU2010308433A1 (en) * 2009-10-23 2012-06-07 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
US8992540B2 (en) 2010-07-22 2015-03-31 Kyphon Sarl Adjustable surgical instruments and methods of use and fabrication
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012166804A1 (en) 2011-06-03 2012-12-06 Reverse Medical Corporation Embolic implant and method of use
WO2014164535A1 (en) 2013-03-11 2014-10-09 Ferry Steven J A guidewire/ partial occluder for intraluminal travel

Also Published As

Publication number Publication date
UA114948C2 (uk) 2017-08-28
NZ711015A (en) 2020-02-28
AR095032A1 (es) 2015-09-16
MX2015011705A (es) 2016-05-18
PH12015501945A1 (en) 2016-01-11
CA2904032A1 (en) 2014-09-12
PL2964200T3 (pl) 2017-09-29
JP6313343B2 (ja) 2018-04-18
IL240579A0 (en) 2015-09-24
MX370175B (es) 2019-12-04
AU2014224238B2 (en) 2016-07-14
KR102233757B1 (ko) 2021-03-30
ZA201505830B (en) 2017-07-26
JP2016510065A (ja) 2016-04-04
CA2904032C (en) 2021-02-16
AU2014224238A1 (en) 2015-09-03
KR20150123248A (ko) 2015-11-03
MA38358A1 (fr) 2016-11-30
BR112015021097B1 (pt) 2022-08-30
MY174648A (en) 2020-05-05
CL2015002466A1 (es) 2016-03-04
US9474534B2 (en) 2016-10-25
ES2634020T3 (es) 2017-09-26
TN2015000386A1 (en) 2017-01-03
CN105073099B (zh) 2018-10-26
WO2014136048A1 (en) 2014-09-12
US10342547B2 (en) 2019-07-09
MA38358B1 (fr) 2017-07-31
US20160045202A1 (en) 2016-02-18
TW201442712A (zh) 2014-11-16
US20160015643A1 (en) 2016-01-21
HK1212244A1 (en) 2016-06-10
SG11201506392VA (en) 2015-09-29
CN105073099A (zh) 2015-11-18
PH12015501945B1 (en) 2016-01-11
EP2964200B1 (en) 2017-04-19
PT2964200T (pt) 2017-07-25
PE20151607A1 (es) 2015-11-26
EA201591649A1 (ru) 2016-01-29
EP2964200A1 (en) 2016-01-13
BR112015021097A2 (pt) 2017-07-18
EA028301B1 (ru) 2017-10-31
IL240579B (en) 2019-08-29

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PH12015501945B1 (en) Formulations of organic compounds
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
PH12015502365A1 (en) Bace1 inhibitors
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
UA117154C2 (uk) Антагоністи s1p3
EA201692298A1 (ru) Производные карбоксамидов
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
TN2015000524A1 (en) Pharmaceutical compositions
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.